Loading ...
Intercytex recently released their annual report which includes details of their hair cloning technique dubbed ICX-TRC.
The Phase II trial of ICX-TRC, their cell therapy product for hair regeneration in male-pattern baldness, began in September 2006. The process involves taking a biopsy from the subject, separating out the relevant cells, and growing them in their facility using a proprietary process.
All biopsies from the first group of 9 patients have been taken and most of these patients have been treated. Further groups will follow to investigate variations in the delivery technique. Intercytex expect to report preliminary data from this trial around the middle of 2007.
In the Phase I trial, which had 7 subjects, there were no safety issues and 5 out of the 7 patients had an increased number of hairs after treatment. The Phase II trials have 10 patients per group and is ongoing. It is an efficacy trial designed to look for new hair growth.
Intercytex has also received a £1.8m grant from the British government to assist in the commercialization of their process.
(6 votes, average: 4.17 out of 5)
Loading ...